drugset / Trial / NCT05553496
Assessment of Rituximab Therapeutic Response Versus Conventional Treatment
RandomizedParallel-groupSingle-blindTreatment
Summary
Prospective interventional comparative study to compare the efficacy of Rituximab versus Conventional treatment in Refractory Nephrotic Syndrome including patients on triple immunosuppression protocols.
Timeline
- Start
- 2022-09-25
- Primary completion
- 2023-04-01
- Completion
- 2023-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Comparator | Dexamethasone | Small molecule | — | — |
Indications
No indication recorded.